Robert L. Keith

Dr. Keith's research interests focus on the early detection and prevention of lung cancer. Specifically, his team is examining prostaglandin manipulation and PPAR gamma agonists in pre‐clinical models of non‐small cell lung cancer, including genetically modified mice. An NCI-sponsored human trial is nearing completion and he recently initiated an immunoprevention trial in high risk subjects. His team's chemoprevention trials include performing bronchoscopy to detect pre‐malignant central airway lesions, and they are better characterizing these lesions to better determine which will progress to invasive lung cancer. This involves characterizing the epithelial cells, the lesional microenvironment, and biomarker discovery/validation.